Background: Musculoskeletal Ultrasonography (MSUS) is now a widely used tool for monitoring of rheumatoid arthritis (RA). Although there are many proposed sets of composite scores, a fixed set of joints may not be an ideal tool to assess a disease like RA, which affects many joints and tendons in different presentations. In previous study (1) U9 score was proven to be correlated with disease activity parameters.

Objectives: To determine whether US assessment using U9 score is useful for monitoring response to treatment for RA or not?

Methods: A prospective, multicenter study were conducted in period from July 2019 to December 2019. All recruited RA patients were subjected to:

- Disease activity assessment by clinical disease activity indices (CDAI and DAS28 ESR).
- Functional status assessment by (HAQ) and ultrasonographic assessment using U9 score which include 8 joints (bilateral wrists, 2nd MCP, 3rd MCP and knees) plus most clinically affected joint or tendon (one joint or one tendon).
- Most clinically affected joints from 48 joints. Any affected tendons could be choosing. All targeted joints were evaluated according to EULAR guidelines and by EULAR/OMERACT combined score (0-3).
- Targeted tendons were scored (0-3). All patients received their treatment (biologic and non biologic DMARDs) according to the decision of the treating physicians. No specific therapy is needed. CDAI and DAS28 ESR, HAQ and U9 score were repeated after 3 months to detect the response to change after receiving the therapy.

Results: One hundred and forty four patients (23.6% were male) with mean age 39.26±11.30 were recruited from 4 referral university hospitals. There was a significant difference (<0.001) between the first and second visits as regards clinical, laboratory and ultrasonographic parameters. DAS 28 decreased from (5.29±1.21) to (3.95±0.99), ESR decreased from (42.12±15.24) to (26.84±13.32), HAQ2 improved from (0.652±0.350) to (0.510±0.237) and U9 total US score decreased from (13.59±5.18) to (8.02±4.28).

Table 1. correlation between U9 ultrasonographic score and clinical parameters.

<table>
<thead>
<tr>
<th></th>
<th>U9 at 1st visit</th>
<th>U9 at 2nd visit</th>
</tr>
</thead>
<tbody>
<tr>
<td>DAS-28</td>
<td>Pearson Correlation 0.806</td>
<td>0.790</td>
</tr>
<tr>
<td></td>
<td>(P value)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>CDAI</td>
<td>Pearson Correlation 0.787</td>
<td>0.773</td>
</tr>
<tr>
<td></td>
<td>(P value)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>HAQ</td>
<td>Pearson Correlation 0.431</td>
<td>0.317</td>
</tr>
<tr>
<td></td>
<td>(P value)</td>
<td>&lt;0.001</td>
</tr>
</tbody>
</table>

We found that the most suitable cut-off value of U9 score to predict high disease activity was 5.5 (sensitivity 83.2% and specificity 88%) and cut-off value for low disease activity was 3.5 (sensitivity 83.3% and specificity 57.1%). These results are summarized in the following table:

Conclusion: U9 ultrasonographic score is very useful method for evaluating the monitoring the response of treatment.

References:

Disclosure of Interests: None declared

DOI: 10.1136/annrheumdis-2020-eular.2936

AB1121 IMPLEMENTING HIGH VALUE CARE IN PATIENT ANTINUCLEAR ANTIBODY TESTING

S. Mumta1, Z. Y. Li1, J. Yoon1, C. Yuvienco.1 University of California, San Francisco Fresno Medical Education Program, Internal Medicine, Fresno, United States of America; 2University of California, San Francisco Fresno Medical Education Program, Rheumatology, Fresno, United States of America

Background: Antinuclear Antibody (ANA) testing forms the basis on which many rheumatological diseases are subsequently diagnosed. ANA testing quantifies the dilution of plasma that produces a specific staining pattern and this can be a part of an ANA order set that reflexively cascades to sub-se- rology if positive. Studies have shown that a low titer ANA may potentially translate into an erroneous diagnosis: if one estimates a 1% prevalence of ANA associated disease in the general population then 30% of those individuals would have a false positive result of ANA detected at 1:40 titer [1]. We theorized that there is no need for several methods to coexist within a single inpatient hospital setting especially since diagnostic value of staining patterns alone is limited.

Objectives: To compare the utility and yield of ‘ANA screening reflex to profile’ (ARP) and ‘ANA reflex to titer’ (ART) order sets in the inpatient setting of a community tertiary care hospital. We aim to identify the appropriateness of the ANA testing ordered including cost-effectiveness of ordering ARP over ART in order to implement the identified quality measures towards improving utilization of ANA testing.

Methods: We identified all inpatient ANA reflex testing orders performed at Community Regional Medical Center, Fresno, California completed between 11/2018 till 07/2019. This included ART and ARP orders with 6 sub-serologies: SSA, SSB, dsDNA, Smith, Scl-70 and U1RNP. A Health Information Management report was generated which included patient’s age, gender, length of hospital stay, dates of testing ordered, principal diagnosis and type of ANA testing ordered. Descriptive statistics were computed and analyzed.

Results: We reviewed a total of 1,012 ANA lab orders performed between 11/01/2018 until 07/30/2019 performed on 700 patients. According to the laboratory standard using Immunofluorescence Assay, an ANA titer starting from 1:40 is reported as positive. Out of the 1,012 tests, 334 tests were positive i.e. 33%. The ART order by itself contributed to 29.9% of the positive testing while ARP formed 70% of the positive testing. 56 of the 910 ARP (6%) performed had one or more sub-serology antibody positive while in 178 ARP orders (20%) only the ANA titer was positive with negative serology. The most common sub-serology antibody noted positive was dsDNA forming 54% of the test orders had one or more sub-serology antibody positive while in 178 ARP orders (20%) only the ANA titer was positive with negative serology. The most common sub-serology antibody noted positive was dsDNA forming 54% of the positive serology results. Multiple testing was noted with 218 orders of ARP and ART being ordered on the same patient within the same week, which shows 21.5% of ANA lab orders were repetitive. Length of stay was noted to be more than 3 days for 89% of the patients who had repetitive testing, majority of those tests (99%) on the same day by the same medical provider. It cost $5.0 for an ART order that resulted negative and $5.0 for an ARP panel that resulted negative. It cost $10.0 for those patients who had both ART and ARP ordered with negative results. A positive ART result added $12.0 additional to the cost of each positive ANA profile ($6736) when both tests were ordered together.

Conclusion: Our study findings reflect the need for using higher yield ANA testing that has been standardized. It demonstrated that physicians ordering the testing were not familiar with the ART vs. ARP, and the laboratory orders without sub-chondralmicrostructures, joint effusion or soft tissue inflammation. 3- Grade 0 Modified Eichenholtz classification system which means normal radiography of the affected foot. Patients with other forms of arthropathy that may mimic Charcot arthropathy e.g. gouty arthritis and rheumatoid arthritis were excluded from the study.Ultrasonographic (grey scale and Doppler US) examination of mid-tarsal and ankle joints was performed according to the EULAR guidelines.

Results: Synovitis and effusion/diad joint were found in all patients and to a lesser extent in the ankle joints. High degree Doppler activity at both ankle and mid tarsal joints could be observed in most patients. Bone erosions were also common as well as tendonitis. A triad of active synovitis (in mid tar- sal joints and ankle joint), active tendonitis (of tibialis posterior and peroneal tendons) and erosions in the distal end of fibula was present in 40 (95.2%) cases.

Conclusion: our study confirms the ability of ultrasonography to detect inflam- matory lesions in early stages of Charcot arthropathy.

Disclosure of Interests: None declared

DOI: 10.1136/annrheumdis-2020-eular.2936